Recently, PKCα inhibition was shown to specifically target cancer stem cells with little effect on the non-cancer stem cells in basal-like breast cancer cell lines, which could prove to be an effective approach in treating aggressive cancers [87]. The gene discussed is PRKCA; the disease is breast carcinoma.